Trials / Completed
CompletedNCT02723071
A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)
An Open-label, Multicentre, Dose-escalating Phase I/II Trial of 3-weekly Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of ocrelizumab in participants with progressive follicular NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ocrelizumab | Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity. |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2016-03-30
- Last updated
- 2016-03-30
Locations
23 sites across 6 countries: Australia, Canada, France, Italy, Sweden, Switzerland
Source: ClinicalTrials.gov record NCT02723071. Inclusion in this directory is not an endorsement.